05:59 AM EST, 11/07/2024 (MT Newswires) -- Cytokinetics ( CYTK ) reported late Wednesday Q3 net loss of $1.36 per share, wider than the $1.35 loss per share a year earlier.

Analysts polled by Capital IQ expected $1.27 loss per share.

Revenue for the quarter ended Sept. 30 was $463,000, up from $378,000 a year earlier.

Analysts polled by Capital IQ expected $1.2 million.

The company had $1.3 billion in cash, cash equivalents, and investments at Sept. 30, it said.